Toward an objective measure of functional disability in dysferlinopathy
Author
dc.contributor.author
Woudt, Lisanne
Author
dc.contributor.author
Di Capua, Gabriella A.
Author
dc.contributor.author
Krahn, Martin
Author
dc.contributor.author
Castiglioni, Claudia
Author
dc.contributor.author
Hughes García, Ricardo
Author
dc.contributor.author
Campero Soffia, Mario
Author
dc.contributor.author
Trangulao, Alejandra
Author
dc.contributor.author
González Hormazabal, Patricio
Author
dc.contributor.author
Godoy Herrera, Raúl
Author
dc.contributor.author
Levy, Nicolas
Author
dc.contributor.author
Urtizberea, Jon Andoni
Author
dc.contributor.author
Jara, Lilian
Author
dc.contributor.author
Bevilacqua, Jorge
Admission date
dc.date.accessioned
2016-06-28T20:35:17Z
Available date
dc.date.available
2016-06-28T20:35:17Z
Publication date
dc.date.issued
2016
Cita de ítem
dc.identifier.citation
Muscle Nerve 53: 49–57, 2016
en_US
Identifier
dc.identifier.other
DOI: 10.1002/mus.24685
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/139174
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Introduction: Understanding the natural history of dysferlinopathy is essential to design and quantify novel therapeutic protocols. Our aim in this study was to assess, clinically and functionally, a cohort of patients with dysferlinopathy, using validated scales. Methods: Thirty-one patients with genetically confirmed dysferlinopathy were assessed using the motor function measure (MFM), Modified Rankin Scale (MRS), Muscle Research Council (MRC) scale, serum creatine kinase (CK) assessment, baseline spirometry data, and echocardiographic and electrophysiologic studies. Results: MFM and MRC scores showed a significant negative correlation with disease duration and inverse correlation with MRS, but not with onset age, clinical phenotype, or CK levels. Percent forced vital capacity (% FVC) correlated negatively with disease duration and onset age. Eight known pathogenic mutations were identified recurrently, 4 of which accounted for 79% of the total. Conclusions: The results suggest that MFM is a reliable outcome measure that may be useful for longitudinal follow-up in dysferlinopathy. Recurrent mutations suggest a founder effect in the Chilean population.